New report examines opioid-related malpractice claims to identify risk factors, warning signs, and vulnerabilities in pain management.
Coverys, a medical liability insurer headquartered in Boston, released a report exploring opioid-related malpractice to identify major risk factors, warning signs, and safety vulnerabilities within the pain management process.
Ann Lambrecht, RN, BSN, JD, FASHRM, and Sharon Gilmore, MHA, BSN, RN-BC, CPHQ, CPHRM, senior risk specialists at Coverys tell Managed Healthcare Executive ®, that Covery wanted to research practice changes that can improve patient safety while reducing malpractice exposure to opioid-prescribing clinicians.
The report examines five years of closed claims, identifying 165 patient events involving opioids, and offers risk management recommendations for each stage.
According to Lambrecht and Gilmore, the report’s main findings were that providers need a specific plan for every step in the medication process and that Coverys’ claims data demonstrates the significant cost of not following national opioid prescribing guidelines.
More findings show:
Related: CCA Shows Success in Managing Members’ Pain and Opioid Use
Opioid events have profound impact on patient outcomes. For example, half of all opioid-related events involve a high severity patient injury, including death. In addition, opioids have caused a profound financial impact of $78.5 billion spent per year, Gilmore and Lambrecht say.
Because of opioids, more than half of all events involve errors in more than one phase of care.
Based on the information in the report, it’s critical that an initial step would be to either perform an opioid medication process self-assessment, which is an assessment to identify exposures existing in an organization.
Briana Contreras is associate editor for Managed Healthcare Executive®.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More